Related Experiment Video

Updated: Jun 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Glycogen synthase kinase 3 beta: can it be a target for oral cancer

Rajakishore Mishra1

  • 1Dept, of Molecular Pharmacology and Therapeutics, Loyola University Medical Center, 2160 South First Avenue, Bldg 102, Maywood, IL-60153, USA. mishrark1@yahoo.co.in

Molecular Cancer
|June 12, 2010
PubMed

Insights

Glycogen synthase kinase 3 beta (GSK3beta) may be a key tumor suppressor in oral cancer. Targeting GSK3beta could offer new therapeutic strategies to combat oral epithelial dysplastic lesions and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Oral cancer treatment has seen limited progress in improving patient outcomes over the last 30 years.
  • Tumor recurrence and metastasis are primary reasons for treatment failure in oral cancer.
  • New therapeutic targets are needed to reverse oral epithelial dysplastic lesions.

Purpose of the Study:

  • To review the multifaceted roles of glycogen synthase kinase 3 beta (GSK3beta) in oral cancer.
  • To explore the potential of GSK3beta as a therapeutic target for oral cancer.
  • To analyze the link between GSK3beta and key oncogenic events in oral cancer.

Main Methods:

  • Literature review of existing research on GSK3beta in human cancers.
  • Analysis of evidence linking GSK3beta to transcription, cell cycle, invasion, metastasis, and apoptosis in oral cancer.
  • Examination of upstream kinases regulating GSK3beta activity and their role in oral cancer etiology.

Main Results:

  • Emerging evidence suggests GSK3beta acts as a tumor suppressor in oral cancer.
  • GSK3beta may regulate critical oncogenic pathways including transcription, cell cycle progression, invasion, metastasis, and apoptosis.
  • Upstream kinases activating GSK3beta are implicated in oral cancer development.

Conclusions:

  • GSK3beta plays a significant role in oral cancer development and progression.
  • Targeting GSK3beta presents a promising therapeutic avenue for oral cancer.
  • Further research is warranted to fully elucidate GSK3beta's role and therapeutic potential in oral cancer.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...